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and in general such differences were not systematic (e.g.
the result for Germany was not always more favourable
than that for the UK). However, if a cost-effectiveness
threshold (i.e. willingness-to-pay) for a life-year or QALY
of $50,000 were assumed, the implications for decision-
making would be similar across countries. CONCLU-
SIONS: It is concluded that, where the analyst allows
factors to vary, cost-effectiveness results differ by country.
However, the implications of such variation for decision-
making depend critically on the cost-effectiveness thresh-
olds applying in Europe.
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Therapeutic innovations are generating increasing pres-
sure on health care budgets particularly for hospitals.
Health care professionals are confronted with budgetary,
ethical and equity issues when no explicit criteria for
choice have been set by the community. Reviews of cost-
advantage proﬁle for costly innovations are rare. OBJEC-
TIVE: This work seeks to analyse propensity and capacity
of health systems to ﬁnance therapeutic innovations
according to their cost/advantages proﬁle. METHODS: A
literature review was carried out. A series of therapeutic
innovations addressing life-threatening conditions were
identiﬁed between 1988 and 2003. They were selected
according to: whether they were considered as innova-
tions at time of their introduction into the market and
their cost high. Forty-four publications in peer-reviewed
journals were selected. Innovations were classiﬁed
according to severity of the condition and the treatment
impact on vital prognosis and survival. Reported costs
were actualised to 2002 values. Common indicators
across studies were identiﬁed. RESULTS: The cost per
year of life saved (YLS) for breast cancer treated for com-
binations including paclitaxel in Europe varies between
€7800 and €14000; at 5 years, the cost for trastuzumab/
paclitaxel association is €23000 in UK. This is between
€7000 and €14000 for ovarian cancer. Cost per YLS 
for myocardial infarctus treated by alteplase in France 
is €12000. It varies between €45000 and €79000 
for implantable cardiac deﬁbrillators. This cost varies
between €10000 to €12000 in Europe and around
€12000 in France for drotrecogin alfa (activated) (recom-
binant human activated protein C) for treatment of severe
sepsis with multiple organ failure, recently launched in
France. CONCLUSIONS: Pharmaco-economic indicators
such as cost per YLS can assist payors in decision-making
process when confronted with costly innovations in
chronic and acute disease. A further step is to consider
the budget impact, taking into account criteria such as
incidence, prevalence, severity, and mortality.
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OBJECTIVES: Financing of hospital services in Germany
is presently transformed to a DRG-based system destined
to derive 100% of the hospital revenue. The aim of this
study is to determine whether the German DRG based
reimbursement provides adequate coverage of actual
costs of intensive care unit (ICU) patients. METHODS:
Retrospective analysis of ICU length of stay (LOS) and
direct cost data extracted from patients’ electronic
records from the surgical ICU of the University Hospital
Göttingen, Germany. Cost calculations performed for
1187 patients with LOS > 24 hours over a 24-month
period (January 1, 2000–Decemeber 31, 2001). ICU reim-
bursement calculations based on the speciﬁc G-DRG
according to the individual diagnosis and the ﬁxed ICU
proportion of the G-DRG reimbursement. Direct variable
cost (consumables) were assessed bottom-up by means of
a patient data management system. Personnel cost were
calculated per day of treatment. Actual total costs were
compared with the hypothetical DRG reimbursement.
RESULTS: Total actual cost for ICU services was €5.58
million (mean per patient: €4697), while the correspond-
ing DRG-based total reimbursement was €2.98 million
(mean per patient: €.513). The cost deﬁcit is statistically
signiﬁcant (P < 0.001). Underfunding of the costs was
evident in most DRG classiﬁcations, some with reim-
bursement deﬁcits of over 80%. These differences showed
a signiﬁcant and negative linear correlation with ICU LOS
(R = -0.593, p < 0.001). CONCLUSIONS: The computed
G-DRG based reimbursement for ICU services differed
signiﬁcantly from the actual costs incurred. These ﬁnd-
ings highlight the importance of a more realistic and fair
DRG-based reimbursement of hospital ICU services in
Germany, particularly with respect to patients with
extended LOS.
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